Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eye injection shows promise for Diabetes-Related vision loss

NCT ID NCT05940428

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times

Summary

This early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes blurry vision in people with diabetes. The main goal is to check the drug's safety and how the body processes it. About 26 adults with DME will receive multiple doses to find the best and safest amount.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

Conditions

Explore the condition pages connected to this study.